Dataset Information


Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE.



Multiple modes of administration are available for systemic lupus erythematosus (SLE) treatments. This study examined patient and physician characteristics associated with the choice of weekly subcutaneous (SC) injection or monthly intravenous (IV) infusion for an unspecified SLE treatment.


This was a cross-sectional, US web-based survey using a direct elicitation, stated-preference methodology (HO-16-16706). Two hundred patients and 200 physicians were asked to choose between IV or SC administration in a hypothetical scenario. Pairwise and multivariate analyses estimated the odds ratio (OR) for the likelihood of choosing SC over IV for respondent characteristics.


Among patients, taking non-steroidal anti-inflammatory drugs increased the likelihood of choosing SC injection (OR 3.884), whilst having SLE-related skin problems, a fear of needles or self-injection, and never needing help around the house decreased the likelihood (OR 0.28, 0.13, 0.12, respectively; all p???0.05). Among physicians, >?95% recommended SC injection for patients who live or work far from an infusion center, prefer SC administration, and never or rarely miss medication doses. Physician characteristics including age and treatment practice also influenced choice.


Patient and physician characteristics influence choice of SC versus IV therapy for SLE. These findings might inform shared decision-making, which could lead to improved patient outcomes. Key Points • Data regarding patient and physician preference for different modes of administration of SLE therapy are sparse. • This cross-sectional, US web-based study showed that patient and physician characteristics influence choice of SC versus IV therapy for SLE. • A degree of disconnect exists between how factors influence patients' choice and how those characteristics influence physicians' choice of SLE treatment mode of administration. • The findings from this study might inform shared decision-making, which could improve alignment between treatment choice and patient preferences, treatment satisfaction, adherence, and improved patient outcomes.


PROVIDER: S-EPMC7817604 | BioStudies | 2021-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5054300 | BioStudies
2017-01-01 | S-EPMC5452285 | BioStudies
2020-01-01 | S-EPMC7585395 | BioStudies
2018-01-01 | S-EPMC6033042 | BioStudies
2016-01-01 | S-EPMC5125609 | BioStudies
2015-01-01 | S-EPMC4524269 | BioStudies
2013-01-01 | S-EPMC4022972 | BioStudies
2020-01-01 | S-EPMC7245774 | BioStudies
2019-01-01 | S-EPMC6380645 | BioStudies
2016-01-01 | S-EPMC4928781 | BioStudies